Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
Br J Cancer. 2013 Sep 3;109(5):1079-84. doi: 10.1038/bjc.2013.446. Epub 2013 Aug 8.
Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES).
Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded.
Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ≥50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ≥50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES.
Abiraterone has important antitumour activity in men with CRPC even after DES exposure.
阿比特龙是去势抵抗性前列腺癌（CRPC）患者的标准治疗方法。我们评估了阿比特龙在合成雌激素己烯雌酚（DES）之后的抗肿瘤活性。
确定了接受阿比特龙治疗的去势抵抗性前列腺癌患者。记录了人口统计学、反应变量和生存数据。
274 名患者接受了阿比特龙治疗，其中 114 名（41.6%）在 DES 之后。在化疗前使用阿比特龙，41 名 DES 初治患者中有 35 名（85.4%）和 27 名 DES 治疗患者中有 20 名（74.1%）出现 PSA 下降≥50%。在多西他赛后使用阿比特龙，113 名 DES 初治患者中有 40 名（35.4%）和 81 名 DES 治疗患者中有 23 名（28.4%）出现 PSA 下降≥50%。无论之前是否使用过 DES，PSA 进展时间均无差异。
即使在 DES 暴露后，阿比特龙对 CRPC 男性也具有重要的抗肿瘤活性。
